# Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

> **NCT00454480** · PHASE2,PHASE3 · COMPLETED · sponsor: **The University of New South Wales** · enrollment: 2000 (estimated)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** alemtuzumab
- **DRUG:** arsenic trioxide
- **DRUG:** azacitidine
- **DRUG:** busulfan
- **DRUG:** clofarabine
- **DRUG:** cytarabine
- **DRUG:** daunorubicin hydrochloride
- **DRUG:** fludarabine phosphate
- **DRUG:** gemtuzumab ozogamicin
- **DRUG:** melphalan
- **DRUG:** tipifarnib
- **GENETIC:** DNA methylation analysis
- **GENETIC:** cytogenetic analysis
- **GENETIC:** gene expression analysis
- **GENETIC:** mutation analysis
- **OTHER:** diagnostic laboratory biomarker analysis
- **OTHER:** immunologic technique
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** nonmyeloablative allogeneic hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT00454480
- **Lead sponsor:** The University of New South Wales
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2012-08
- **Final completion:** —
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2013-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454480, "Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00454480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*